You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR3 positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

Breast Cancer Metastatic, Hormone Receptor Positive Malignant Tumor of Breast Trial in Spain (Combination, Rogaratinib +

Recruiting
  • Breast Cancer Metastatic
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • Combination, Rogaratinib + palbociclib + fulvestrant
  • Hospitalet de Llobregat, Barcelona, Spain
  • +7 more
Feb 8, 2022

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Bladder Cancer Trial in Vandœuvre-lès-Nancy (Urine collection (150ml), Blood sample (20 ml))

Recruiting
  • Bladder Cancer
  • Urine collection (150ml)
  • Blood sample (20 ml)
  • Vandœuvre-lès-Nancy, France
    Institut de Cancérologie de Lorraine
Mar 23, 2022

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Urinary Bladder Tumors, Tumor Metastasis, Ureteral Tumors Trial in New York, Myrtle Beach, Nashville (LOXO-435, Pembrolizumab)

Recruiting
  • Urinary Bladder Neoplasms
  • +2 more
  • New York, New York
  • +2 more
Jan 31, 2023

Bladder Cancer Trial in Indianapolis, Baltimore, Rockledge (Dovitinib)

Terminated
Has Results
  • Bladder Cancer
  • Indianapolis, Indiana
  • +2 more
Jul 7, 2022

Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation Trial in United States (Erdafitinib)

Recruiting
  • Bladder Cancer
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 22, 2022

Gastrointestinal Cancer Trial in Tianjin (Pemigatinib)

Recruiting
  • Gastrointestinal Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Dec 7, 2022

Advanced Non Small Cell Lung Cancer Trial (Sintilimab, Pemigatinib)

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • (no location specified)
Aug 6, 2021

Refractory Solid Tumors Trial in Seoul (sunitinib)

Completed
  • Refractory Solid Tumors
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jun 13, 2022

Advanced or Metastatic Solid Tumor Trial in Worldwide (Rogaratinib (BAY1163877), Copanlisib (BAY80-6946))

Completed
  • Advanced or Metastatic Solid Tumor
  • Rogaratinib (BAY1163877)
  • Copanlisib (BAY80-6946)
  • Los Angeles, California
  • +19 more
Jul 13, 2022

Anhedonia Trial in Winnipeg (PVSET)

Enrolling by invitation
  • Anhedonia
  • PVSET
  • Winnipeg, Manitoba, Canada
    Deer Lodge Centre
Sep 6, 2023

Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial in

Recruiting
  • Advanced Hepatocellular Carcinoma
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 30, 2023

HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

Not yet recruiting
  • HER-2 Positive Advanced Solid Tumors
  • D3L-001
  • (no location specified)
Jul 20, 2023

Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy Trial in Arlington Heights (Panzyga IVIG,

Not yet recruiting
  • Small Fiber Neuropathy
  • +3 more
  • Panzyga IVIG
  • Placebo
  • Arlington Heights, Illinois
    Northwest Community Healthcare
Aug 22, 2022

Characterization of Anti-FGFR3 Antibodies

Recruiting
  • Sensory Peripheral Neuropathy
  • Neurological assessment and Blood sample
  • Bordeaux, France
  • +16 more
May 17, 2021

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Multiple Myeloma, Relapsed/Refractory Trial in Toronto (JNJ-42756493, Dexamethasone)

Terminated
  • Multiple Myeloma
  • Relapsed/Refractory
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Sep 15, 2020

SSTR2, FAP, Positron-Emission Tomography Trial in Xiamen (18F-FDG PET/CT, 68Ga-FAPI-LM3 PET/CT)

Recruiting
  • SSTR2
  • +2 more
  • 18F-FDG PET/CT, 68Ga-FAPI-LM3 PET/CT
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
May 24, 2023

Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • Palo Alto, California
  • +9 more
Aug 2, 2022

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023